<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">27721525</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0091-4509</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>43</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Contemporary drug problems</Title>
                <ISOAbbreviation>Contemp Drug Probl</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Harm Reduction From Below: On Sharing and Caring in Drug Use.</ArticleTitle>
            <Pagination>
                <MedlinePgn>199-215</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>This article focuses on how recreational drug users in the Netherlands and in online communities navigate the risks and reduce the harms they associate with psychoactive drug use. To do so, we examined the protective practices they invent, use, and share with their immediate peers and with larger drug experimenting communities online. The labor involved in protective practices and that which ultimately informs <i>harm reduction from below</i> follows three interrelated trajectories: (1) the handling and sharing of drugs to facilitate <i>hassle-free</i> drug use, (2) creating pleasant and friendly spaces that we highlight under the practices of <i>drug use attunements</i>, and (3) the seeking and sharing of information in practices to <i>spread the good high</i>. We focus not only on users' concerns but also on how these concerns shape their approach to drugs, what young people do to navigate uncertainties, and how they reach out to and create different sources of knowledge to minimize adversities and to improve highs. Harm reduction from below, we argue, can best be seen in the practices of <i>sharing</i> around drug use and in the <i>caring</i> for the larger community of drug-using peers.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Van Schipstal</LastName>
                    <ForeName>Inge</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Amsterdam Institute for Social Science Research, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mishra</LastName>
                    <ForeName>Swasti</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Amsterdam Institute for Social Science Research, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berning</LastName>
                    <ForeName>Moritz</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Amsterdam Institute for Social Science Research, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murray</LastName>
                    <ForeName>Hayley</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Amsterdam Institute for Social Science Research, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>07</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Contemp Drug Probl</MedlineTA>
            <NlmUniqueID>0323553</NlmUniqueID>
            <ISSNLinking>0091-4509</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">NPS</Keyword>
            <Keyword MajorTopicYN="N">designer drugs</Keyword>
            <Keyword MajorTopicYN="N">harm reduction</Keyword>
            <Keyword MajorTopicYN="N">party drugs</Keyword>
            <Keyword MajorTopicYN="N">user experience</Keyword>
            <Keyword MajorTopicYN="N">virtual communities</Keyword>
        </KeywordList>
        <CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>06</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>07</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27721525</ArticleId>
            <ArticleId IdType="doi">10.1177/0091450916663248</ArticleId>
            <ArticleId IdType="pii">10.1177_0091450916663248</ArticleId>
            <ArticleId IdType="pmc">PMC5046163</ArticleId>
        </ArticleIdList>
        <?pmcsd?>
        <ReferenceList>
            <Reference>
                <Citation>CNS Drugs. 2001;15(3):231-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11463130</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nordisk Alkohol Nark. 2011 Dec 21;28(5-6):433-452</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22308079</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Alcohol Rev. 2007 Nov;26(6):673-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17943528</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Harm Reduct J. 2013 Oct 02;10:18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24088321</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anthropol Med. 2014;21(2):107-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25175289</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Drug Policy. 2006 Jan 1;17(1):23-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23543728</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World Psychiatry. 2015 Jun;14(2):248</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26043347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Drug Policy. 2007 May;18(3):213-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17689368</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Drug Policy. 2013 May;24(3):223-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23352335</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Drug Policy. 2008 Oct;19(5):353-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17728122</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Aust J Public Health. 1993 Mar;17(1):58-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8357896</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Drug Policy. 2007 Mar;18(2):107-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17689353</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Harm Reduct J. 2014 Sep 08;11:25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25200686</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Drug Issues. 2009 Jun;39(3):495-522</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20686669</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Alcohol Rev. 2012 Jun;31(4):566-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22168668</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Drug Policy. 2009 Sep;20(5):402-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19168342</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Subst Use Misuse. 2008;43(1):55-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18189205</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cult Med Psychiatry. 2000 Jun;24(2):165-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10885786</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>